About Osiris Therapeutics
Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: OSIR
- CUSIP: 68827R10
Companies Related to Osiris Therapeutics:
- Previous Close: $5.66
- 50 Day Moving Average: $5.44
- 200 Day Moving Average: $5.20
- 52-Week Range: $3.55 - $7.87
- Trailing P/E Ratio: 134.76
- Foreward P/E Ratio: 80.86
- P/E Growth: 0.00
- Market Cap: $195.00M
- Outstanding Shares: 34,452,000
- Beta: 0.79
What is Osiris Therapeutics' stock symbol?
Osiris Therapeutics trades on the NASDAQ under the ticker symbol "OSIR."
Where is Osiris Therapeutics' stock going? Where will Osiris Therapeutics' stock price be in 2017?
1 analysts have issued 1-year price targets for Osiris Therapeutics' shares. Their predictions range from $4.00 to $4.00. On average, they expect Osiris Therapeutics' stock price to reach $4.00 in the next twelve months.
When will Osiris Therapeutics announce their earnings?
Osiris Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April, 7th 2016.
What are analysts saying about Osiris Therapeutics stock?
Here are some recent quotes from research analysts about Osiris Therapeutics stock:
According to Zacks Investment Research, "Osiris’ third quarter loss was wider-than-expected. The company also said that certain factors impacted third quarter revenues. Although we are encouraged by Osiris' efforts to grow the Biosurgery segment, dependence on a single segment for growth is concerning. Moreover, Osiris is evaluating Grafix for additional indications and disappointing data would have an adverse impact on the shares. Meanwhile, we are positive on Osiris’ deals with Arthrex and Stryker for Cartiform and BIO4, respectively. We are also positive on the company’s sale of its ceMSC business which has not only brought in cash for Osiris in the form of an upfront payment but will also bring in royalties. Expanded sales force, improving Medicare and private reimbursement coverage should drive revenues." (4/11/2016)
Brean Capital analysts commented, "Last night after the close, OSIR issued an 8-K indicating that it will not be able to file its 10- K on time, nor within the 15 day extension period, putting the stock at risk for de-listing with NASDAQ. They also indicated all of 2014 through 3Q15 should not be relied upon and will require restatements—not very surprising since 2014 though 2Q15 were already deemed unreliable due to revenue recondition issues, though up until yesterday 3Q15 was conspicuously deemed reliable. Finally, the company was subpoenaed by the SEC as part of an investigation into accounting practices, and the related accounting issues have precipitated 2 additional lawsuits. While we had warned of the likelihood of such delays in filings (hence our Sell rating), we remain cautious on the company’s ability to remedy these issues and re-issue reliable financial statements. This will likely be a protracted process, creating at least several quarters of uncertainty. In such situations, stocks trade at 1x sales at best (implying $4), but this may prove optimistic given the uncertainty over the 2016 revenue outlook. We are projecting 13% revenue growth, which is now in doubt due to management changes (resignations of the CEO and COO and its related disruption), unreliability of numbers, and some revenues from residual Ovation sales ($7.6 million as of 3Q) that will not re-occur in 2016." (3/16/2016)
Who owns Osiris Therapeutics stock?
Osiris Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.40%), State Street Corp (0.84%), FMR LLC (0.44%), GSA Capital Partners LLP (0.14%), State Board of Administration of Florida Retirement System (0.07%) and Horizon Kinetics LLC (0.06%).
Who sold Osiris Therapeutics stock? Who is selling Osiris Therapeutics stock?
Osiris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC.
Who bought Osiris Therapeutics stock? Who is buying Osiris Therapeutics stock?
Osiris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP and State Street Corp.
How do I buy Osiris Therapeutics stock?
Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Osiris Therapeutics stock cost?
One share of Osiris Therapeutics stock can currently be purchased for approximately $5.66.